Cosmetic & Dermatologic

Definition

Cosmetic and dermatologic peptides are compounds primarily used to improve skin structure, reduce signs of aging, or modulate dermatological inflammation. Unlike most other peptide categories, compounds here are predominantly applied topically or locally rather than systemically, and many have well-characterized safety profiles from decades of cosmetic industry use. This category spans three distinct mechanisms: extracellular matrix remodeling (GHK-Cu), neuromodulatory wrinkle reduction (Argireline), and anti-inflammatory receptor signaling (KPV).

Mechanism of Action

GHK-Cu (copper tripeptide-1, Gly-His-Lys complexed with Cu²⁺) is the most mechanistically characterized peptide in personal care. It activates tissue remodeling by stimulating collagen types I and III synthesis, glycosaminoglycan production, and angiogenesis. It modulates matrix metalloproteinase activity (increasing MMPs for tissue remodeling while suppressing excess degradation) and influences the transcription of over 4,000 genes related to tissue repair, inflammation, and energy metabolism. Argireline (acetyl hexapeptide-3, a hexapeptide derived from the N-terminal end of SNAP-25) inhibits SNARE complex assembly, reducing acetylcholine release at neuromuscular junctions — a mild, reversible botulinum-like effect that reduces expression-line depth. KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminus of alpha-MSH that acts as a melanocortin receptor agonist to suppress NF-κB-driven inflammation in skin, gut, and other epithelial tissues.

Regulatory Status

GHK-Cu and Argireline are classified as cosmetic ingredients (International Nomenclature Cosmetic Ingredient system) — they are not regulated as drugs when used topically. Injectable GHK-Cu preparations require compounding pharmacy involvement. KPV is used in research and compounding contexts but has no FDA drug approval; when used topically, it falls under cosmetic classification.

Evidence Base

Topical GHK-Cu has the strongest evidence of the three: randomized controlled trials in photoaging and observational studies in wound healing support its efficacy for elasticity improvement, firmness, and fine line reduction. Argireline has cosmetic RCT data demonstrating measurable reduction in forehead line depth with repeated application. KPV's anti-inflammatory evidence is primarily from cell culture and animal GI studies (IBD models); human dermatological evidence is limited. Systemic injectable applications for any compound in this category have thinner clinical evidence than topical use.